346 filings
Page 4 of 18
SC 13D/A
lhue0
9 Jan 24
Kymera Therapeutics / BIOTECHNOLOGY VALUE FUND L P ownership change
4:45pm
4
x6txh5 sf0
5 Jan 24
Kymera Therapeutics / Ellen Chiniara ownership change
5:15pm
8-K
pd3wz83ui
5 Jan 24
Kymera Therapeutics Announces Proposed Public Offering
4:11pm
424B5
imda83bb3t40gwgr8p9d
5 Jan 24
Prospectus supplement for primary offering
4:02pm
424B5
0e45ix3 twekxu
4 Jan 24
Prospectus supplement for primary offering
4:06pm
8-K
xterpq d5aj2qsox9kr
4 Jan 24
Regulation FD Disclosure
4:01pm
144
68l516piv e9pve
4 Jan 24
Notice of proposed sale of securities
9:29am
8-K
j55n dplblk3vwtmmmk
4 Jan 24
STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024
7:08am
4
p0jec 0gcdj
2 Jan 24
Kymera Therapeutics / Nello Mainolfi ownership change
5:43pm
4
axywrk2vzzmhew99g
6 Nov 23
Kymera Therapeutics / MARK N LAMPERT ownership change
6:07pm
4
um58d71s108 o9didhv
6 Nov 23
Kymera Therapeutics / Nello Mainolfi ownership change
6:00pm
8-K
x5wh xk6wn3qabxoqbro
2 Nov 23
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
9:15am
8-K
dy4a p0vk1imv
2 Nov 23
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
7:10am
4
oixh3w9 dazvm
8 Aug 23
Kymera Therapeutics / Nello Mainolfi ownership change
4:30pm
8-K
uf7afuzqd rqct2
3 Aug 23
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
7:10am
4
kxq 81oh7p78lkk49
20 Jun 23
Kymera Therapeutics / MARK N LAMPERT ownership change
5:55pm
4
ret4806u
20 Jun 23
Kymera Therapeutics / Victor Sandor ownership change
4:16pm
4
zyz7 6sist
20 Jun 23
Kymera Therapeutics / Leigh Morgan ownership change
4:15pm